Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.

Autoimmunity reviews - 1 Apr 2016

Ramanathan Sudarshini, Dale Russell C, Brilot Fabienne

Abstract excerpt

Myelin oligodendrocyte glycoprotein (MOG) is a protein exclusively expressed on the surface of oligodendrocytes and myelin in the central nervous system. MOG has been identified as a putative candidate autoantigen and autoantibody target in demyelination for almost three decades, with extensive literature validating its role in murine models of experimental autoimmune encephalomyelitis. Seminal studies using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to Autoantigens
Share to Biomarkers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MOG gene

Share to Multiple Sclerosis

Share to Multiple Sclerosis Research Studies

Share to Myelin-Oligodendrocyte Glycoprotein

Share to Phenotype

Source

Identifiers

PMID: 26708342
DOI: 10.1016/j.autrev.2015.12.004

Genes

MOG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.PMID 26708342Read ↗

Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating DiseasesSemantic proximity Read ↗

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe FormsSemantic proximity Read ↗

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosisSemantic proximity Read ↗

Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.Semantic proximity Read ↗

The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis.Semantic proximity Read ↗

Myelin Oligodendrocyte Glycoprotein–Associated DisordersSemantic proximity Read ↗

[Clinical features and modern diagnostic criteria of the disease associated with myelin oligodendrocyte glycoprotein antibody disease].Semantic proximity Read ↗

Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination.Semantic proximity Read ↗

Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosisSemantic proximity Read ↗

The Potential Pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the Optic PathwaySemantic proximity Read ↗

E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.Semantic proximity Read ↗

MOGAD update: new phenotypes in the expanding clinical spectrum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.